CA125 Outperforms HE4 and CA19-9 as a Serum Biomarker for Preoperative Diagnosis of Ovarian Endometriomas: A Retrospective Cohort Study

article OA: closed CC0
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-07-23 ⓘ

Serum CA125 demonstrated superior diagnostic performance in distinguishing ovarian endometriomas from other benign ovarian tumors compared to HE4 and CA19-9.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-08-15 · read from full text ⓘ

This retrospective cohort study evaluated the diagnostic performance of serum CA125, HE4, and CA19-9 in distinguishing ovarian endometriomas from other benign ovarian tumors among 654 patients with histologically confirmed cysts. The results indicated that CA125 levels were significantly higher in patients with endometriomas compared to those with non-endometriotic benign cysts, demonstrating excellent discriminatory power with an area under the curve of 0.895. In contrast, HE4 showed only moderate utility while CA19-9 lacked significant value for differentiating these conditions. The authors noted that the retrospective design limits the interpretation of findings but recommended integrating CA125 as a routine biochemical adjunct to ultrasonography for preoperative assessment. This paper is centrally about endometriosis — specifically the preoperative differential diagnosis of ovarian endometriomas using serum biomarkers.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Accurate pre-operative discrimination between ovarian endometriomas (EMs) and other benign ovarian tumors is crucial for surgical planning and fertility counseling. This study aimed to evaluate the diagnostic performance of serum CA125, CA19-9, and HE4 in differentiating endometriomas from non-endometriotic benign ovarian cysts. This retrospective cohort study included 654 patients with histologically confirmed benign ovarian cysts (343 endometriomas and 311 other benign ovarian tumors) from January 2024 to March 2025. Serum CA125, CA19-9, and HE4 levels were compared between groups. Receiver operating characteristic (ROC) analysis was performed to assess diagnostic accuracy, with stratified analyses by age, dysmenorrhea, cyst laterality, and parity. Patients with endometriomas had significantly elevated CA125 (median: 56.40 vs. 17.30 U/mL, P<0.001) and HE4 (31.50 vs. 14.94 pmol/L, P<0.001), whereas CA19-9 showed no significant difference. ROC analysis revealed that CA125 had excellent diagnostic performance (AUC=0.895; sensitivity=85.7% (95% CI: 81.6-89.2%); specificity=80.6% (95% CI: 75.8-84.9%) at cutoff=27.45 U/mL), consistently superior across all subgroups. HE4 demonstrated moderate utility (AUC=0.683), while CA19-9 lacked discriminatory value. Serum CA125 reliably distinguishes endometriomas from other benign ovarian tumors across diverse clinical scenarios. CA125 should be routinely integrated as a biochemical adjunct to ultrasonography, whereas HE4 and CA19-9 have limited clinical utility in this context. The retrospective design of this study should be considered when interpreting the findings.
Full text 6,280 characters · extracted from oa-doi-fallback · 2 sections · click to expand

Abstract

Accurate pre-operative discrimination between ovarian endometriomas (EMs) and other benign ovarian tumors is crucial for surgical planning and fertility counseling. This study aimed to evaluate the diagnostic performance of serum CA125, CA19-9, and HE4 in differentiating endometriomas from non-endometriotic benign ovarian cysts. This retrospective cohort study included 654 patients with histologically confirmed benign ovarian cysts (343 endometriomas and 311 other benign ovarian tumors) from January 2024 to March 2025. Serum CA125, CA19-9, and HE4 levels were compared between groups. Receiver operating characteristic (ROC) analysis was performed to assess diagnostic accuracy, with stratified analyses by age, dysmenorrhea, cyst laterality, and parity. Patients with endometriomas had significantly elevated CA125 (median: 56.40 vs. 17.30 U/mL, P<0.001) and HE4 (31.50 vs. 14.94 pmol/L, P<0.001), whereas CA19-9 showed no significant difference. ROC analysis revealed that CA125 had excellent diagnostic performance (AUC=0.895; sensitivity=85.7% (95% CI: 81.6-89.2%); specificity=80.6% (95% CI: 75.8-84.9%) at cutoff=27.45 U/mL), consistently superior across all subgroups. HE4 demonstrated moderate utility (AUC=0.683), while CA19-9 lacked discriminatory value. Serum CA125 reliably distinguishes endometriomas from other benign ovarian tumors across diverse clinical scenarios. CA125 should be routinely integrated as a biochemical adjunct to ultrasonography, whereas HE4 and CA19-9 have limited clinical utility in this context. The retrospective design of this study should be considered when interpreting the findings. Similar content being viewed by others

References

Baumler M, Heiss N, Druckmann R. Endometriosis at all ages: diagnostic ultrasound. Horm Mol Biol Clin Investig. 2022;43(2):151–7. Guan Q, Velho RV, Sehouli J, Mechsner S. Endometriosis and opioid receptors: are opioids a possible/promising treatment for endometriosis? Int J Mol Sci 2023;24(2):1633. Li W, Feng H, Yang X, Meng Y, Yang Y, Ye Q. The effects of music therapy on pain and anxiety in young nulliparous patients undergoing laparoscopic cystectomy for endometriosis: a randomized controlled trial. J Psychosom Obstet Gynaecol. 2025;46(1):2519385. Li T, Hou N, Mao L, Liu F, Ma Z, Wang L, Xu X, Yan G, Han Y, Wei J. Tumor markers in differential diagnosis of benign ovarian masses. Int J Womens Health. 2024;16:1517–31. Rokhgireh S, Mehdizadeh Kashi A, Chaichian S, Delbandi AA, Allahqoli L, Ahmadi-Pishkuhi M, Khodaverdi S, Alkatout I. The diagnostic accuracy of combined Enolase/Cr, CA125, and CA19-9 in the detection of endometriosis. Biomed Res Int 2020;2020:5208279. Micu R, Gaia-Oltean AMI, Budisan L, Braicu C, Irimie A, Berindan-Neagoe I. The added value of CA125, HE4, and CA72-4 as markers for ovarian endometriosis diagnosis. Rom J Morphol Embryol. 2023;64(2):159–64. Abdul Karim AK, Abd Aziz NH, Md Zin RR, Mohd Mokhtar N, Shafiee MN. The effect of surgical intervention of endometriosis to CA-125 and pain. Malays J Med Sci. 2020;27(6):7–14. Sethi A, Kumar L, Mathur S, Mahey R, Kachhawa G, Bhatla N. Prognostic significance of HE4 tissue expression in serous epithelial ovarian carcinoma. South Asian J Cancer. 2022;11(2):125–32. Han Y, Jiang L, Liu K, Ouyang L, Li Y. Predictive value of HE4 in platinum-based chemotherapy for ovarian cancer: a systematic review. Front Oncol. 2021;11:703949. Zhang X, Nie D, Zhang L, Liu X. Study on diagnostic values and pathological conditions of serum HGF and CA199 in endometriosis. Am J Transl Res. 2021;13(4):2849–57. Kokot I, Piwowar A, Jedryka M, Solkiewicz K, Kratz EM. Diagnostic significance of selected serum inflammatory markers in women with advanced endometriosis. Int J Mol Sci 2021;22(5):2295. Guo C, Zhang C. Platelet-to-lymphocyte ratio and CA125 level as a combined biomarker for diagnosing endometriosis and predicting pelvic adhesion severity. Front Oncol. 2022;12:896152. Zhu H, Wang Y, He Y, Yu W. Inflammation-mediated macrophage polarization induces TRPV1/TRPA1 heteromers in endometriosis. Am J Transl Res. 2022;14(5):3066–78. Zhang L, Liu Y, Xu Y, Wu H, Wei Z, Cao Y. The expression of the autophagy gene beclin-1 mRNA and protein in ectopic and eutopic endometrium of patients with endometriosis. Int J Fertil Steril. 2015;8(4):429–36. Anastasi E, Farina A, Granato T, Colaiacovo F, Pucci B, Tartaglione S, Angeloni A. Recent insight about HE4 role in ovarian cancer oncogenesis. Int J Mol Sci 2023;24(13):10479. Rowswell-Turner RB, Singh RK, Urh A, Yano N, Kim KK, Khazan N, Pandita R, Sivagnanalingam U, Hovanesian V, James NE, et al. HE4 overexpression by ovarian cancer promotes a suppressive tumor immune microenvironment and enhanced tumor and macrophage PD-L1 expression. J Immunol. 2021;206(10):2478–88. Chen T, Wei JL, Leng T, Gao F, Hou SY. The diagnostic value of the combination of hemoglobin, CA199, CA125, and HE4 in endometriosis. J Clin Lab Anal. 2021;35(9):e23947. Funding There was no external funding for this study. Author information Authors and Affiliations Corresponding author Ethics declarations Human Ethics This study was conducted as a retrospective analysis and has received ethical approval from the Third Affiliated Hospital of Sun Yat-sen University (No.II2025-179-01). Conflict of interest On behalf of all authors, the corresponding author states that there is no conflict of interest. Additional information Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Rights and permissions Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. About this article Cite this article He, H., Yang, X., Li, Y. et al. CA125 Outperforms HE4 and CA19-9 as a Serum Biomarker for Preoperative Diagnosis of Ovarian Endometriomas: A Retrospective Cohort Study. Reprod. Sci. (2026). https://doi.org/10.1007/s43032-026-02115-6 Received: Accepted: Published: Version of record: DOI: https://doi.org/10.1007/s43032-026-02115-6

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

MeSH descriptors

CA-125 Antigen CA-125 Antigen CA-125 Antigen CA-125 Antigen CA-125 Antigen CA-125 Antigen CA-125 Antigen CA-125 Antigen CA-125 Antigen CA-125 Antigen CA-125 Antigen CA-125 Antigen CA-125 Antigen CA-125 Antigen CA-125 Antigen CA-125 Antigen CA-125 Antigen CA-125 Antigen CA-125 Antigen CA-125 Antigen

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (14)

Source provenance

europepmc
last seen: 2026-09-27T09:11:36.575535+00:00
openalex
last seen: 2026-08-10T06:04:38.217482+00:00
pubmed
last seen: 2026-09-30T06:11:30.291506+00:00
unpaywall
last seen: 2026-09-29T06:34:56.587159+00:00
License: CC0 · commercial use OK